Evidence map›Paper›PMID 33178019›Full record

ReviewFrontiers in pharmacology2020

Nephrotoxicity of Herbal Medicine and Its Prevention.

Xiaofen Xu, Ruyi Zhu, Jialiang Ying, Mengting Zhao, Xin Wu, Gang Cao, Kuilong Wang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xiaofen XuSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
Ruyi ZhuSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
Jialiang YingSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
Mengting ZhaoSchool of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Xin WuSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
Gang CaoSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
Kuilong WangSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
Zhejiang Chinese Medical University · CNGuizhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herbal medicine (HM) has been widely used to treat diseases for thousands of years and has greatly contributed to the health of human beings. Many new drugs have been developed from HM, such as artemisinin. However, artemisinin has adverse effects, such as renal toxicity. In 1993, a study conducted in Belgium reported for the first time that the root extracts of Aristolochia obliqua S. M. Hwang led to progressive interstitial renal fibrosis. The nephrotoxicity of HM has attracted worldwide attention. More than 100 kinds of HM induce renal toxicity, including some herbs, animal HMs, and minerals. This paper aimed to summarize the HM compounds that cause nephrotoxicity, the mechanisms underlying the toxicity of these compounds, biomarkers of renal injury, and prevention strategies. These findings provide a basis for follow-up studies on the prevention and treatment of HM nephrotoxicity.

Indexed as

herbal medicinenephrotoxicityprevention strategiestoxic componentstoxicity mechanism

Identifiers

PMID33178019
PMCPMC7593559
OpenAlexW3092794643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.